Europe — EMA
Octreoscan (Indium In-111 Pentetreotide)
Indium In-111 pentetreotide, the active ingredient in Octreoscan, is a somatostatin analog presented as a radiopharmaceutical for intravenous use.
Request sourcing
What is Indium In-111 Pentetreotide?
Indium In-111 pentetreotide, the active ingredient in Octreoscan, is a somatostatin analog presented as a radiopharmaceutical for intravenous use. It is employed in diagnostic imaging to locate neuroendocrine tumors and assess disease extent in adult patients. GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
What is Indium In-111 Pentetreotide used for?
Octreoscan is a radiolabeled somatostatin analogue used in nuclear medicine to image neuroendocrine tumor pathways.
- Gastroenteropancreatic neuroendocrine tumors: helps detect and stage the extent of disease. - Carcinoid syndrome tumors: assists in localising primary and metastatic lesions. - Medullary thyroid carcinoma: aids in identifying somatostatin‑receptor positive lesions. - Small‑cell lung cancer: supports visualisation of somatostatin‑expressing lesions. - Neuroendocrine metastases: evaluates distribution of metastatic disease.
What are the side effects of Indium In-111 Pentetreotide?
Side effects are generally mild and related to the radiopharmaceutical nature of the product.
Common Side Effects: - Nausea - Transient flushing of the skin - Mild headache or dizziness - Injection site pain - Low‑grade fever - Fatigue
Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) . - Significant hypotension - Acute renal failure . - Hematologic toxicity (e.g., thrombocytopenia). - Radiation‑induced organ damage . - Persistent vomiting.
What precautions apply to Indium In-111 Pentetreotide?
Octreoscan should be administered g g \
